Best Practice & Research Clinical Rheumatology
Volume 24, Issue 1 , Pages 107-119 , February 2010

Targeted therapies in osteoarthritis: a systematic review of the trials on www.clinicaltrials.gov

  • Francis Berenbaum, MD, PhD (Director)

      Affiliations

    • Corresponding Author InformationDepartment of Rheumatology, Saint-Antoine Hospital, 184 rue du faubourg Saint-Antoine, 75012 Paris, France. Tel.: +33 1 49 28 25 20; Fax: +33 1 49 28 25 13.

References 

  1. Michon M, Sellam J, Berenbaum F. Targeted therapies in osteoarthritis. In: Weisman Michael H, Weinblatt Michael E, Louie James S, van Vollenhoven Ronald F, (editors), Targeted Treatment of Rheumatic Diseases. Vol. 1 (in press).
  2. Hefti FF, Rosenthal A, Walicke PA, et al. Novel class of pain drugs based on antagonism of NGF. Trends Pharmacol Sci. 2006 Feb;27(2):85–91
  3. Seidel MF, Herguijuela M, Forkert R, et al. Nerve growth factor in rheumatic diseases. Sem Arthritis Rheum. 2009 May 27;
  4. Whiteside GT, Lee GP, Valenzano KJ. The role of the cannabinoid CB2 receptor in pain transmission and therapeutic potential of small molecule CB2 receptor agonists. Curr Med Chem. 2007;14(8):917–936
  5. Guindon J, Hohmann AG. Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain. Br J Pharmacol. 2008 Jan;153(2):319–334
  6. Andreou AP, Holland PR, Goadsby PJ. Activation of iGluR5 kainate receptors inhibits neurogenic dural vasodilatation in an animal model of trigeminovascular activation. Br J Pharmacol. 2009 Jun;157(3):464–473
  7. Nilius B, Voets T, Peters J. TRP channels in disease. Sci STKE. 2005 Aug 2;2005(295):re8
  8. Stuckya CL, Dubinb AE, Jeskec NA, et al. Roles of transient receptor potential channels in pain. Brain Res Rev. 2009;60:2–23
  9. Remadevi R, Szallisi A. Adlea (ALGRX-4975), an injectable capsaicin (TRPV1 receptor agonist) formulation for long-lasting pain relief. IDrugs. 2008 Feb;11(2):120–132
  10. Meini CA. Maggi Knee osteoarthritis: a role for bradykinin?. Inflamm Res. 2008;57:351–361 S
  11. Cawston TE, Wilson AJ. Understanding the role of tissue degrading enzymes and their inhibitors in development and disease. Best Pract Res Clin Rheumatol. 2006 Oct;20(5):983–1002
  12. Krzeski P, Buckland-Wright C, Balint G, et al. Development of musculoskeletal toxicity without clear benefit after administration of PG 116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: a randomized, 12 month, double-blind, placebo-controlled study. Arthritis Res Ther 2007;9:R109.
  13. Boileau C, Martel-Pelletier J, Brunet J, et al. Oral treatment with PD-0200347, an alpha2delta ligand, reduces the development of experimental osteoarthritis by inhibiting metalloproteinases and inducible nitric oxide synthase gene expression and synthesis in cartilage chondrocytes. Arthritis Rheum. 2005 Feb;52(2):488–500
  14. Salminen-Mankonen HJ, Morko J, Vuorio E. Role of Cathepsin K in normal joints and in the development of arthritis. pp. 315–323 (9) Curr Drug Targets. 2007 Feb;8(2):315–323
  15. Chubinskaya S, Hurtig M, Rueger DC. OP-1/BMP-7 in cartilage repair. Int Orhop. 2007;31(6):773–781
  16. Moore EE, Bendele AM, Thompson DL, et al. Fibroblast growth factor-18 stimulates chondrogenesis and cartilage repair in a rat model of injury-induced osteoarthritis. Osteoarthritis Cartilage. 2005;13(7):623–631
  17. Granholm S, Lundberg P, Lerner UH. Expression of the calcitonin receptor, calcitonin receptor-like receptor, and receptor activity modifying proteins during osteoclast differentiation. J Cell Biochem. 2008 Jun 1;104(3):920–933
  18. Karsdal MA, Sondergaard BC, Arnold M, et al. Calcitonin affects both bone and cartilage: a dual action treatment for osteoarthritis?. Ann N Y Acad Sci. 2007 Nov;1117:181–195
  19. Holick MF. Vitamin D deficiency. N Engl J Med. 2007 Jul 19;357(3):266–281
  20. Jacques C, Gosset M, Berenbaum F, et al. The role of IL-1 and IL-1Ra in joint inflammation and cartilage degradation. Vitam Horm. 2006;74:371–403
  21. Chevalier X, Goupille P, Beaulieu AD, et al. Intra-articular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2009 Mar 15;61(3):344–352
  22. Feldmann M, Maini SR. Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics. Immunol Rev. 2008 Jun;223:7–19
  23. Madi L, Cohen S, Ochayin A, et al. Overexpression of A3 adenosine receptor in peripheral blood mononuclear cells in rheumatoid arthritis: involvement of nuclear factor-kappaB in mediating receptor level. J Rheumatol. 2007 Jan;34(1):20–26
  24. Lane NE, Schnitzer TJ, Brown MT. Tanezumab relieves moderate to severe pain due to Osteoarthritis (OA) of the knee: a phase 2. Trial Arthritis Rheum. 2008;(Suppl.)

PII: S1521-6942(09)00082-5

doi: 10.1016/j.berh.2009.08.007

Best Practice & Research Clinical Rheumatology
Volume 24, Issue 1 , Pages 107-119 , February 2010

Article Tools

* Image Usage & Resolution